Ranbaxy, Russian region sign MoU on healthcare cooperation

Ranbaxy Laboratories Ltd, India's largest Pharmaceutical company, and the government of Yaroslavl region in Russia today signed a memorandum of understanding (MoU) on cooperation in the field of healthcare and medical science.

Under the MoU, the two will cooperate in the areas of healthcare system in the Yaroslav region, new medical technologies, including expansion of educational programmes for the medical and pharmaceutical community, collaboration in the field of clinical trials as well as improvement in drug safety monitoring in medical practice.

Ranbaxy will, initially, evaluate collaborations with local academic and research centres in Yaroslavl region to broaden its scope of medical educational programmes for professional medical and pharmaceutical community. It will also look at cooperation in the area of clinical; trials as well as participation in any created clinical trial centre, Ranbaxy said in filing with the Bombay Stock Exchange (BSE).

The Yaroslavl region is establishing a pharmaceutical zone and is encouraging pharmaceutical companies to set up manufacturing facilities and conduct clinical trials.

"We are delighted to explore potential opportunities in Yaroslavl to build and strengthen the local pharmaceutical industry," said Arun sawhney, managing director of Ranbaxy.

Ranbaxy has been present in the Russian pharmaceuticals market for around 20 years. The company has registered 51 drugs in the Russian Federation and commercialised 72 SKUs. The company offers products covering therapeutic segments such as anti-bacterial, gastroenterology, analgesics, cardiovasculars, HIV/ AIDS, metabolic disorders etc.